Please login to the form below

Not currently logged in
Email:
Password:

reimbursement models

This page shows the latest reimbursement models news and features for those working in and with pharma, biotech and healthcare.

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

The antibiotic treats infections caused by aerobic Gram-negative bacteria. Shionogi’s novel antibiotic Fetcroja has been selected for inclusion in a pilot subscription reimbursement scheme, launched by the UK’s ... Shionogi strongly supports the

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Man vs microbe: the fight against antimicrobial resistance Man vs microbe: the fight against antimicrobial resistance

    The payer perception. On average, payers rate innovative reimbursement models as being slightly more impactful than amending HTA pathways at addressing AMR (Figure 1). ... Payers recognise value in the approaches adopted by the UK and Germany, suggesting

  • Reimbursement ≠ patient access Reimbursement ≠ patient access

    In our experience, creating future- proof reimbursement strategies now relies heavily on achieving two critical components. ... Launch activities will have to include data capture on a product’s performance and patient outcomes to satisfy future

  • Building a brighter future with patient support programmes Building a brighter future with patient support programmes

    This opens up the opportunity to run a really targeted clinical study and get strong outcomes, which lifts a drug’s chances of succeeding through the regulatory process and reimbursement.”. ... Reports by analysts Deloitte underscore the value of

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    Any of these issues can increase cost or risk. Adapting pricing and reimbursement models to accommodate these therapies could be a significant challenge, especially for higher-cost drugs or those involving ... Manufacturers will need to restructure

  • No incentive for a cure No incentive for a cure

    Each of the different models are variations of a fee-for-service reimbursement model, which have evolved to meet the needs of chronic illnesses. ... Incremental changes may work in the short-term. Incremental changes include solutions such as

More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...